Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
5.04
+0.86 (20.57%)
At close: Mar 9, 2026, 4:00 PM EDT
5.02
-0.02 (-0.40%)
After-hours: Mar 9, 2026, 4:14 PM EDT
Lisata Therapeutics Revenue
Lisata Therapeutics had revenue of $1.07M in the twelve months ending September 30, 2025. In the year 2024, Lisata Therapeutics had annual revenue of $1.00M.
Revenue (ttm)
$1.07M
Revenue Growth
n/a
P/S Ratio
34.46
Revenue / Employee
$41,154
Employees
26
Market Cap
44.46M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Atara Biotherapeutics | 151.93M |
| Celularity | 40.58M |
| Xilio Therapeutics | 31.80M |
| NovaBay Pharmaceuticals | 10.30M |
| CervoMed | 6.16M |
| Actinium Pharmaceuticals | 90.00K |
| INmune Bio | 50.00K |
LSTA News
- 2 days ago - Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewsWire
- 5 weeks ago - Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - GlobeNewsWire
- 4 months ago - Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 4 months ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 4 months ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire